ADHD requires a multimodal treatment approach and effective pharmacological management is often a component of this treatment.

CADDRA has received reports from healthcare professionals indicating a decrease in the degree and length of symptom control and increase in side effects when patients are switched from first-line ADHD medication Concerta to its generic equivalent (Novo-Methylphenidate ER-C). Similar reports have been received by the Centre for ADHD Advocacy, Canada (CADDAC) from caregivers and patients.

If you have noted this - or any other Adverse Event (AE) - with a prescribed medication, CADDRA recommends filing an Adverse Reaction Form with Health Canada. Unlike the US Food and Drug Administration (FDA), Health Canada has no mechanism to review an issue such as reduced symptom control. It requires official AE reporting of a decrease in effectiveness of a generic medication when compared to the brand medication before action can occur.